ISRCTN51421587 https://doi.org/10.1186/ISRCTN51421587

Swiss VISCOsupplementation Trial 1

Submission date
14/05/2004

Recruitment status
No longer recruiting

Registration date
12/07/2004

Overall study status
Completed

Last Edited
07/12/2007

Condition category
Musculoskeletal Diseases

[ ] Prospectively registered
[ ] Protocol
[ ] Statistical analysis plan
[X] Results
[ ] Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Peter Juni

Contact details
Departments of Social and Preventive Medicine and Rheumatology
University of Berne
Finkenhubelweg 11
Berne
Switzerland
3012
juni@ispm.unibe.ch

Additional identifiers

Study information

Scientific Title

Acronym
SVISCOT-1

Study objectives

To determine the comparative effectiveness, cost-utility and safety of preparations with different chemical structures and origins used for viscosupplementation in knee Osteoarthritis (OA).

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration.

Primary study design
Interventional

Study design
Randomised controlled trial

Study type(s)
Treatment

Health condition(s) or problem(s) studied
Osteoarthritis (OA) of the knee

Interventions
Patients will be allocated to one of three different preparations, a cross-linked formulation (Synvisc®) and non-cross-linked preparations of different origin (Orthovisc® and Ostenil®). Patients will undergo up to three treatment cycles per knee (one cycle consisting of three injections), with not more than one treatment cycle per knee every 6 months and the last injection administered not later than 18 months post-randomisation.

Intervention Type
Drug

Phase
Not Specified

Drug/device/biological/vaccine name(s)
Orthovisc®, Ostenil®, Synvisc®

Primary outcome(s)
Western Ontario and McMaster Universities osteoarthritis index (WOMAC) pain sub-scores.

Key secondary outcome(s)
Cost-utility based on health related quality of life measured by EuroQoL and self-reported healthcare utilisation for osteoarthritis

Completion date
31/12/2004

Eligibility

Key inclusion criteria
1. Men and non-pregnant women with radiologically confirmed symptomatic OA of the knee for at least 6 months
2. Pain on most days for the previous 3 months
3. Fulfil American College of Rheumatology (ACR) clinical criteria for OA of the knee:
3.1. Have an ACR functional class rating of II to IV
3.2. Failed to respond sufficiently
3.3. Intolerant to conservative treatment

Participant type(s)
Patient

Healthy volunteers allowed
No

Age group
Not Specified

Sex
All

Key exclusion criteria
Not provided at time of registration.

Date of first enrolment
01/05/2002

Date of final enrolment
31/12/2004

Locations

Countries of recruitment
Switzerland

Study participating centre
Departments of Social and Preventive Medicine and Rheumatology
Berne
Switzerland
3012

Sponsor information

Organisation
Swiss Federal Office of Social Insurance (OFAS) (Switzerland)

ROR
https://ror.org/03zv4m970

Funder(s)

Funder type
Government

Funder Name
The Swiss Federal Office of Social Insurances (Switzerland) - funding protocol development and implementation

Funder Name
The manufacturers do not provide any funding for the trial.

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	Results	01/11/2007		Yes	No
Study website	Study website	11/11/2025	11/11/2025	No	Yes